Prognostic Signature and Tumor Immune Landscape of N7-Methylguanosine-Related lncRNAs in Hepatocellular Carcinoma

• DOI: 10.3389/fgene.2022.906496
• Publication Date: 2022-07-22T12:33:28Z
• Authors: Wei Wei; Chao Liu; Meng Wang; Wei Jiang; Caihong Wang; Shuqun Zhang
• Keywords: Signature (topology)

Despite great advances in the treatment of liver hepatocellular carcinoma (LIHC), such as immunotherapy, prognosis remains extremely poor, and there is an urgent need to develop novel diagnostic prognostic markers. Recently, RNA methylation-related long non-coding RNAs (lncRNAs) have been demonstrated be potential biomarkers for tumor diagnosis well immunotherapy response, N6-methyladenine (m6A) 5-methylcytosine (m5C). N7-Methylguanosine (m7G) a widespread modification eukaryotes, but relationship between m7G-related lncRNAs LIHC patients response still unknown. In this study, based on patients' clinical transcriptomic data from TCGA database, total 992 that co-expressed with 22 m7G regulatory genes were identified using Pearson correlation analysis. Univariate regression analysis was used screen lncRNAs, least absolute shrinkage selection operator (LASSO) multivariate Cox applied construct 9-m7G-related-lncRNA risk model. The lncRNA model validated exhibit good performance through Kaplan-Meier ROC Together clinicopathological features, score found independent factor LIHC. Furthermore, high-risk group unveiled higher mutation burden (TMB), their microenvironment more prone immunosuppressive state exhibited lower rate immunotherapy. addition, 47 anti-cancer drugs difference drug sensitivity low-risk groups. Taken together, might display value predicting prognosis, patients.